A5010333539- Blood Coagulation and Thrombosis Mechanisms
- Venous Thromboembolism Diagnosis and Management
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Atrial Fibrillation Management and Outcomes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiovascular Issues in Pregnancy
- Hemoglobinopathies and Related Disorders
- Atherosclerosis and Cardiovascular Diseases
- Central Venous Catheters and Hemodialysis
- Monoclonal and Polyclonal Antibodies Research
- Blood properties and coagulation
- Herpesvirus Infections and Treatments
- Chronic Myeloid Leukemia Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Maternal and fetal healthcare
- Cancer-related gene regulation
- Intramuscular injections and effects
- Cytomegalovirus and herpesvirus research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cardiac Arrhythmias and Treatments
- Systemic Lupus Erythematosus Research
- Shoulder Injury and Treatment
- Pregnancy and Medication Impact
- Hematopoietic Stem Cell Transplantation
Hôpital de l'Enfant-Jésus
2006-2018
Centre hospitalier universitaire de Québec
2014-2018
Soroka Medical Center
2017
University of Ottawa
2015
Ottawa Hospital Research Institute
2015
Ottawa Hospital
2015
Hôpital du Saint-Sacrement
1999-2007
Université Laval
1991-2005
Centre hospitalier de l'Université Laval
1998
McMaster University
1991-1993
The risk of recurrence is lower after treatment an episode venous thromboembolism associated with a transient factor, such as recent surgery, than permanent, or no, factor. Retrospective analyses suggest that 1 month anticoagulation adequate for patients whose thromboembolic event was provoked by factor.In this double-blind study, who had completed anticoagulant therapy first factor were randomly assigned to continue warfarin placebo additional 2 months. Our goal determine if the duration...
Summary von Willebrand disease ( VWD ) is a bleeding disorder that occurs in up to 1% of the general population. The great majority females with experience menorrhagia. morbidity burden may relate iron deficiency resulting from To explore relationships between disorders, menorrhagia, and outcomes health‐related quality life HRQL educational attainment. All subjects , other Canadian national registry who were more than 12 years age eligible for survey. Survey measures included HEALTH...
ABSTRACT The performance of a commercially available qualitative PCR test for plasma (AMPLICOR CMV Test; Roche Diagnostics) and quantitative leukocytes (COBAS AMPLICOR MONITOR was evaluated with samples from 50 blood or marrow allogeneic transplant recipients who received short courses sequential ganciclovir therapy (2 weeks intravenously followed by 2 orally) based on positive cytomegalovirus (CMV) pp65 antigenemia (AG) assay. number persons significantly higher leukocyte-based assays (AG,...
BACKGROUND: Canada's publicly funded blood system has recently introduced high‐purity concentrates as the standard treatment for individuals with hemophilia. The added cost and need to document patient outcomes have prompted consideration of a national product monitoring system. STUDY DESIGN AND METHODS: This study investigates suitability Canadian Hemophilia Registry (CHR) basis such by assessing degree which it represents users factor concentrates. RESULTS: Currently, there are 1978...
ABSTRACT Fifty allogeneic stem cell transplant recipients were enrolled in a prospective cytomegalovirus pp65 antigenemia-guided preemptive therapy trial. Among these, 10 of 34 patients who received ganciclovir exhibited sustained and/or recurrent antigenemia despite treatment. Thirteen leukocyte preparations from these subjects screened for the presence most frequent UL97 mutations conferring resistance. None detected after mean and median exposures 31.6 28.0 days, respectively.
Summary. Two retrospective studies have suggested that exposure to factor VIII (FVIII) in early infancy is associated with an increased risk of FVIII inhibitor development. We prospectively studied 11 infants who needed replacement therapy for bleeding episodes before the age 2 years. They received activated recombinant VII (rFVIIa) concentrate on demand, intention postponing their first after years age. Thirty‐three were treated 154 doses rFVIIa no evidence adverse effect. Bleeding was...
<h3>Background:</h3> The use of subcutaneous heparin, the therapy choice for women requiring anticoagulant prophylaxis during pregnancy, is problematic because discomfort produced by repeated injections. An indwelling Teflon catheter that can be left in place 1 week recently became available as an entry port parenteral therapy. Since this has potential to overcome some problems long-term heparin therapy, we decided compare with twice-daily injections pregnancy. <h3>Methods:</h3> In a...
Considerable maternal and perinatal mortality morbidity are associated with placental-mediated pregnancy complications. Preventative options limited. Because thrombosis is frequently observed in the uteroplacental circulation of women complications, a number studies have investigated anticoagulation therapy using unfractionated heparin or low-molecular-weight as preventative option. Most such were conducted thrombophilia; limited data available for without thrombophilia unconvincing. This...
Introduction Following a provincial tender, most subjects with haemophilia A in Quebec switched their treatment to third‐generation recombinant B‐domain‐deleted factor VIII ( FVIII ). Aim Our objective was evaluate the incidence of inhibitor development and recovery patients following switch replacement therapy. Methods One hundred thirty‐five were enrolled tested for activity inhibitors every 6 months during 1 year. Subjects mild or current excluded. Data on demographics, bleeds usage...
Picosecond photoinduced absorption in BaTiO3 has been observed for the first time to our knowledge using picosecond laser pulses and a delay pump–probe technique. The pump intensity dependence as well of coefficient have measured. results can be explained qualitatively by secondary-center model. From results, hole recombination with secondary centers is not larger than 60 ps.